TanyaMTrippettMD

Pediatric Hematology & Oncology • New York, NY

Associate Attending Pediatrician

Overview of Dr. Trippett

Dr. Tanya Trippett is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and NYC Health + Hospitals / Bellevue. She received her medical degree from Duke University School of Medicine and has been in practice 32 years. She is one of 95 doctors at Memorial Sloan Kettering Cancer Center and one of 14 doctors at NYC Health + Hospitals / Bellevue who specialize in Pediatric Hematology & Oncology. She also speaks multiple languages, including French. She has more than 60 publications and over 500 citings.

Office
1275 York Avenue
New York, NY 10065
Book by Phone+1(913) 534-8125

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1988 - 1991
Duke University HospitalResidency, Pediatrics, 1985 - 1988
Duke University School of MedicineClass of 1985

Certifications & Licensure

NJ State Medical License 2023 - 2025
NY State Medical License 1995 - 2024
NC State Medical License 1987 - 1998
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2014
New York Magazine: Top Doctors Castle Connolly, 2013-2014

Clinical Trials

Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma Start of enrollment: 1995 Aug 01
Completed
Phase 2
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma Start of enrollment: 1996 Jan 01
Completed
Phase 2
Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma Start of enrollment: 1999 Jan 01
Completed
Phase 2
Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma Start of enrollment: 2001 May 01
Completed
Phase 2
Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation Start of enrollment: 2004 May 01
Terminated
Phase 1
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors Start of enrollment: 2004 Sep 01
Completed
Phase 1
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens Start of enrollment: 2006 Jul 01
Terminated
Phase 2
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma Start of enrollment: 2007 Nov 13
Completed
Phase 2
Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II) Start of enrollment: 1994 Mar 01
Completed
Phase 2
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH Start of enrollment: 1995 Jan 01
Completed
Phase 2
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942) Start of enrollment: 1996 Mar 01
Completed
Phase 2
LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma Start of enrollment: 1990 May 01
Completed
Phase 2
Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors Start of enrollment: 2008 Oct 01
Completed
Phase 1
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas Start of enrollment: 2009 Oct 30
Completed
Phase 2
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Start of enrollment: 2011 Feb 09
Completed
Phase 1, Phase 2
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
A Safety Study of SGN-CD19A for Leukemia and Lymphoma Start of enrollment: 2013 Feb 01
Completed
Phase 1
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment Start of enrollment: 2016 Oct 01
Active, not recruiting
Phase 1, Phase 2
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children Start of enrollment: 2016 Feb 16
Completed
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

68 citations
Tumour extracellular vesicles and particles induce liver metabolic dysfunction.
Gang Wang, Jianlong Li, Linda Bojmar, Haiyan Chen, Zhong Li
Nature. 2023-06-01
4 citations
Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab.
Arash Nabbi, Arnavaz Danesh, Osvaldo Espin-Garcia, Stephanie Pedersen, Johanna Wellum
Nature Cancer. 2023-04-01
22 citations
Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study.
Tanya Trippett, Helen Toledano, Quentin Campbell Hewson, Arnauld Verschuur, Anne-Marie Langevin
Targeted Oncology. 2022-05-01

Press Mentions

$Article on Anti-Tumor Activity of PV-10 Against Relapsed and Refractory Neuroblastoma Published in OncoTargets and Therapy$
Article on Anti-Tumor Activity of PV-10 Against Relapsed and Refractory Neuroblastoma Published in OncoTargets and TherapyFebruary 19th, 2019
Paediatric Cancer Centre for GhanaMarch 30th, 2017
First International Paediatric Cancer Centre for GhanaMarch 29th, 2017
Join now to see all